Hormae Pharma

Hormae Pharma, founded in November 2020 in Lyon, France, is a privately held biotech company specializing in the development of small molecule therapeutics aimed at targeting cellular receptors that control the latency replication balance of Epstein-Barr Virus (EBV). The company's core mission is to prevent and treat EBV-induced pathologies, which include malignancies of lymphoid and epithelial cell origins as well as autoimmune diseases such as multiple sclerosis. Hormae Pharma's proprietary library of receptor ligands was designed and synthesized by one of its co-founders at Edelris. The founders, who are scientists with extensive backgrounds in immunology, virology, and medicinal chemistry, have a proven track record in the creation and management of biopharmaceutical companies. The company's business model revolves around the research and development of these therapeutics, with revenue generated through partnerships, licensing agreements, and potential future sales of their products. Hormae Pharma primarily serves the healthcare and pharmaceutical markets, targeting medical professionals and institutions involved in the treatment of EBV-related conditions.

Keywords: EBV, small molecule therapeutics, immunology, virology, medicinal chemistry, biotech, lymphoid malignancies, autoimmune diseases, receptor ligands, biopharmaceutical.